Completed OBSERVATIONAL NCT05386459

Study of the Use of the Drug Ingaron in Patients With COVID-19

Prospective Two-week Open-label Application Experimental Randomized Single-center Non-interventional Study of the Drug Ingaron in Patients With a New Coronavirus Infection COVID-19

Sponsor: SPP Pharmaclon Ltd.

Conditions COVID-19 Respiratory Infection Viral Pneumonia

Interventions Interferon Gamma

Updated 4 times since 2022 Last updated: May 23, 2022 Started: Apr 21, 2020 Primary completion: Jun 17, 2020 Completion: Oct 1, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on COVID-19 Respiratory Infection and Viral Pneumonia, this trial is completed. The trial is conducted by SPP Pharmaclon Ltd. and has accumulated 4 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jun 2022 — Jul 2024 [monthly]

Completed

First recorded

Apr 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SPP Pharmaclon Ltd.

Data source: SPP Pharmaclon Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia